Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

Koffiekamer Terug naar discussie overzicht

TG Therapeutics TGTX

8 Posts
| Omlaag ↓
  1. Forecast2006 6 februari 2023 10:16

    • Forecast2006

      Lid sinds: 30 mrt 2006

      Laatste bezoek: 17 feb 2025

    • Aanbevelingen

      Ontvangen: 330

      Gegeven: 463

    •    Aantal posts: 2.112

    By Sriparna Roy and Khushi Mandowara

    (Reuters) - TG Therapeutics (NASDAQ:TGTX) Inc said on Wednesday that the U.S. health regulator had approved its monoclonal antibody for treating patients with relapsing forms of multiple sclerosis, sending its shares up 47% in afternoon trade.

    The approval by the U.S. Food and Drug Administration (FDA) widens the number of such drugs available for treating the disorder to three and may help soften the blow to the company's finances from the withdrawal of its lymphatic cancer drug earlier this year.

    TG Therapeutics said it was expecting to launch the drug, branded as Briumvi, in the first quarter of 2023, but did not give details on its pricing.

    Jefferies analyst Chris Howerton said ahead of the approval that he was expecting the drug to be priced in the range of $30,000 per patient per year. In comparison, Roche's Ocrevus has a current list price of about $68,000 annually.

    Multiple sclerosis is a neurological disease in which the immune system attacks the brain cells causing motor disabilities. It affects about 400,000 people in the United States, according to the National Institutes of Health.

    Unlike other MS drugs that target T cells, Briumvi belongs to a class of drugs that tackles B cells' role in driving the inflammation that is central to the neurological disease.

    The approval, which comes with a warning of infusion reactions from the drug, was based on a late-stage study that showed the drug was effective in reducing the annualized relapse rates in patients.

    Ben benieuwd wat ie vandaag doet.

    Kind regards,

    Forecast
  6. Forecast2006 17 februari 2023 19:53

    • Forecast2006

      Lid sinds: 30 mrt 2006

      Laatste bezoek: 17 feb 2025

    • Aanbevelingen

      Ontvangen: 330

      Gegeven: 463

    •    Aantal posts: 2.112


    U.S. FDA approves TG Therapeutics' multiple sclerosis drug; shares surge
    Stock Markets Dec 28, 2022 03:20PM ET

    U.S. FDA approves TG Therapeutics' multiple sclerosis

    By Sriparna Roy and Khushi Mandowara

    (Reuters) - TG Therapeutics (NASDAQ:TGTX) Inc said on Wednesday that the U.S. health regulator had approved its monoclonal antibody for treating patients with relapsing forms of multiple sclerosis, sending its shares up 47% in afternoon trade.

    The approval by the U.S. Food and Drug Administration (FDA) widens the number of such drugs available for treating the disorder to three and may help soften the blow to the company's finances from the withdrawal of its lymphatic cancer drug earlier this year.

    TG Therapeutics said it was expecting to launch the drug, branded as Briumvi, in the first quarter of 2023, but did not give details on its pricing.

    Jefferies analyst Chris Howerton said ahead of the approval that he was expecting the drug to be priced in the range of $30,000 per patient per year. In comparison, Roche's Ocrevus has a current list price of about $68,000 annually.

    Multiple sclerosis is a neurological disease in which the immune system attacks the brain cells causing motor disabilities. It affects about 400,000 people in the United States, according to the National Institutes of Health.

    Unlike other MS drugs that target T cells, Briumvi belongs to a class of drugs that tackles B cells' role in driving the inflammation that is central to the neurological disease.

    The approval, which comes with a warning of infusion reactions from the drug, was based on a late-stage study that showed the drug was effective in reducing the annualized relapse rates in patients.
  7. Forecast2006 18 februari 2023 14:46

    • Forecast2006

      Lid sinds: 30 mrt 2006

      Laatste bezoek: 17 feb 2025

    • Aanbevelingen

      Ontvangen: 330

      Gegeven: 463

    •    Aantal posts: 2.112

    Feb 14, 2023
    NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab) in adult patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 23 – 25, 2023, in San Diego, California. Abstracts are now available online and can be accessed on the ACTRIMS meeting website at www.forum.actrims.org. Details of the presentations are outlined below.

    Poster Presentation Title: Early, Transient Shift in Hematologic Parameters Observed with Ublituximab in the ULTIMATE I and II Phase 3 Studies

    Presentation Date/Time: Thursday, February 23, 7:00 - 7:30 PM PST
    Session: Poster Session 1
    Abstract Number/Poster Number: 406/P071
    Lead Author: Peiqing Qian, MD, Swedish Neuroscience Institute, Seattle, WA

    CONTACT:

    Investor Relations
    Email: ir@tgtxinc.com
    Telephone: 1.877.575.TGTX (8489), Option 4

    Media Relations:
    Email: media@tgtxinc.com
    Telephone: 1.877.575.TGTX (8489), Option 6

    Kind regards,
    Forecast
  8. Forecast2006 29 februari 2024 09:17

    • Forecast2006

      Lid sinds: 30 mrt 2006

      Laatste bezoek: 17 feb 2025

    • Aanbevelingen

      Ontvangen: 330

      Gegeven: 463

    •    Aantal posts: 2.112

    Flinke stijging van de koers van 26,74 % na 4e kwartaalcijfers die beter waren dan de analisten hadden verwacht.
    Hoop dat het medicijn BRIUMVI MS patiënten gaat helpen.
    Kind regards,
    Forecast
8 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.076
AB InBev 2 5.521
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.747
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.755
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 191
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.754
Aedifica 3 919
Aegon 3.258 322.885
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.895
Agfa-Gevaert 14 2.051
Ahold 3.538 74.342
Air France - KLM 1.025 35.086
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.042
Alfen 16 24.933
Allfunds Group 4 1.502
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.823
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.396
AMG 971 133.716
AMS 3 73
Amsterdam Commodities 305 6.697
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.017
Apollo Alternative Assets 1 17
Apple 5 383
Arcadis 252 8.785
Arcelor Mittal 2.034 320.776
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.326
Aroundtown SA 1 219
Arrowhead Research 5 9.745
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.287
ASML 1.766 108.169
ASR Nederland 21 4.502
ATAI Life Sciences 1 7
Atenor Group 1 514
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.688
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.404